CARMAT SAS Publishes Its Third Shareholder Newsletter
This latest issue gives readers an opportunity to discover three activities that are inherent to the
CARMAT heart's development through interviews with:
• Professor Daniel Duveau, Medical Director of the Thorax Institute and of the Thoracic and Vascular surgery department at the Nantes CHU* Nord Laennec university hospital, regarding his collaboration with CARMAT for more than a decade;
• Mr Laurent Le Portz, Chairman & CEO of Vignal Artru Industries, who tells us about the main aspects of his company's partnership with CARMAT for the development of the electro-hydraulic pump system;
• Mr Mohamed-Tahar Zaghdoud, Head of the software division, one of CARMAT's strategic divisions.
Last but not least, in the "Shareholders' questions" section CARMAT gives the floor to its shareholders and answers their most frequently-asked questions.
To discover CARMAT's third Shareholder Newsletter, please go to the Company's website:
www.carmatsa.com.
About CARMAT: CARMAT, the world's most advanced total artificial heart project.
The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.
The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.
Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life. A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.
Strongly committed, prestigious founders and shareholders: Truffle Capital(the leading European venture capital firm), EADS, the Foundation Alain Carpentier, the Marie Lannelongue Cardiothoracic Centreand the thousands of institutional and individual shareholders who have placed their trust in CARMAT.
* Centre Hospitalier Universitaire (university hospital)
For more information: www.carmatsa.com